Without doubt, the importance of ultrasound has increased in many areas in recent years. On the one hand, ultrasound examination as a simple procedure without risk has become an essential part of the clinical routine. Thus, for example, the emergent area of focused ultrasound with a clearly definable target issue is becoming increasingly important for basic diagnosis. On the other hand, highly detailed differential diagnoses can be made in all application areas, particularly in prenatal diagnosis. Consequently, it is important to adapt continuing training guidelines, create uniform recommendations, and update these on an ongoing basis. Therefore, guidelines for interventional ultrasound, an update of rare gastrointestinal diseases, and recommendations for the use of noninvasive prenatal testing (NIPT) as a screening method for fetal chromosomal abnormalities in clinical practice are a main focus of this edition. NIPT, in particular, which was made possible by the discovery of cell-free DNA in maternal blood in 1997 and the subsequent development of high throughput sequencing methods, has kept patients, physicians, labs, and medical societies on their toes – hardly another prenatal examination has been included in clinical care so quickly after its development. Although current numbers are largely based on data of commercial providers and the outcome of large series is not available in the majority of cases, the value of NIPT is undisputed and allows the identification of trisomy 21 with a sensitivity of over 99 % (lower for trisomies 13 and 18). As a result, NIPT seems superior to other risk screening methods, such as first trimester screening, and has already resulted in a significant reduction of invasive interventions and thus intervention-related miscarriages. However, given all the enthusiasm, there is a risk of overestimating the diagnostic significance of the test. Contrary to the promises of an increase in performance due to technology improvements, NIPT will never be diagnostic in its current form since the fetal DNA is of a placental origin and thus the occurrence of mosaicism that can result in false-positive or false-negative findings is biologically determined. Particularly in the case of the often advertized examination of sex chromosomes, in particular the X-chromosome, this phenomenon leads to a low positive predictive value (PPV) of a pathological result. This is also true for the detection of microdeletions, which is associated with a low PPV and a high false-positive rate due to the structure of our genome, thus repeatedly resulting in false-positive findings with this method and consequently in additional invasive procedures. The public interest in NIPT and the uncontrolled market of supply and demand have quickly also shown the negative effects of overenthusiasm, such as premature reassurance of a pregnant woman, for example when a normal NIPT at 10 – 11 gestational weeks is followed by ultrasound findings of an increased nuchal translucency at 13 – 14 gestational weeks or findings of a heart defect. In addition, there is a risk of a false sense of security and testing in a less differentiated manner following a normal NIPT. A lack of coordination with late diagnoses and incomplete knowledge and education of pregnant women regarding test performance can also create new problems. An experienced examiner typically diagnoses trisomy 18 and 13 on ultrasound in the 11th-14th gestational week and the detection rate of experts for these two chromosomal abnormalities should be significantly higher than after NIPT. If a high risk for these trisomies is determined after first trimester screening, a differentiated ultrasound control possibly with subsequent rapid karyotyping would provide results faster than NIPT, save time and costs for NIPT, and decrease the period of uncertainty for pregnant women. Therefore, there is a certain risk that patient care will not improve in particular if prenatal diagnosis only concentrates on the three most common trisomies. Since this test is not diagnostic, the significance of marker screening after a normal NIPT such as measurement of the fetal nasal bone and the ratio of the prenasal skin thickness to the nasal bone length in the first and second trimester as addressed in two studies in this edition must be determined. On the one hand, case studies show that rare undetected fetuses with trisomy 21 or mosaic findings were first identified by this approach. On the other hand, there is a lack of studies showing that the continued use of marker screening does not result in an increase of the false-positive rate. A basic principle of screening in pregnancy is the multi-stage concept or the option of reference to a reference center. The idea is to refer pregnancies with a particularly high risk to centers for a second opinion. Presumably this concept significantly contributed to the improvement of the early diagnosis of fetal malformations. In Switzerland, these developments have been taken into account and the reimbursement of costs for NIPT by the obligatory health insurance under certain conditions has been regulated by the Federal Office of Public Health (FOPH) after consultation with experts. The test is restricted to the three most common trisomies and a prior ultrasound scan is required. In the case of a high nuchal translucency, growth restriction, or fetal malformations, NIPT per se as a screening test is not indicated since other causes than the three most common trisomies must be considered. Particularly in pregnancies with fetal anomalies, the etiology is often not clear at the time of diagnosis, but the determination of an isolated or syndromal genesis is decisive for prognosis assessment and the question regarding continuation of the pregnancy. The use of genomic microarrays after invasive diagnostic methods that allow high-resolution chromosome testing has brought a significant advance in diagnostics. In...